Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04162353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 16, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 2021 to Jul 2026
    • Start date changed from estimate of May 2021 to Jul 1, 2019
    v4
  2. Start date: Nov 2019 to May 2021
    • Collaborators: 1 to 2
    v3
  3. Eligibility criteria shortened, about 9 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Trial Details
NCT Number NCT04162353
Lead Sponsor iCell Gene Therapeutics
Collaborators: iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital
Conditions
(from sponsor)		 Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma
Related terms Lymphoma, Multiple Myeloma
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov